Abstract Number: 0015 • ACR Convergence 2021
Rheumatoid Factor Recognizes Specific Domains of IgG Heavy Chain Complexed with HLA Class II Molecules
Background/Purpose: Rheumatoid factor (RF) is an autoantibody that binds to IgG Fc region (CH2 and CH3 domains) and is detectable in patients with rheumatoid arthritis…Abstract Number: 0033 • ACR Convergence 2021
Impaired Adipose Tissue Function in Rheumatoid Arthritis: Association with Autoimmunity, Disease Activity and Therapeutic Response
Background/Purpose: 1) to evaluate the relationship among adipose tissue dysfunction, autoimmunity and disease activity in rheumatoid arthritis (RA) patients; 2) to analyze the direct effect…Abstract Number: 0097 • ACR Convergence 2021
Outcome of SARS-CoV-2 Infection in Patients with Rheumatoid Arthritis Under Treatment with Janus Kinase Inhibitors Compared to Tumour Necrosis Factor Inhibitors
Background/Purpose: Janus kinase inhibitors (JAK-i) offer a potent mode of action to treat rheumatic diseases. Little is known on the course and outcome of SARS-CoV-2…Abstract Number: 0171 • ACR Convergence 2021
Bone Erosions and Osteophytes in Premenopausal Women with Long-standing Rheumatoid Arthritis: Association with Systemic Bone Involvement Using HR-pQCT
Background/Purpose: Two patterns of bone involvement are described in rheumatoid arthritis (RA), systemic and localized. Systemic bone involvement is characterized by loss of generalized bone…Abstract Number: 0272 • ACR Convergence 2021
RA Disease Activity Is an Independent Predictor of Left Ventricular Mass Changes in an RA Cohort Without Cardiovascular Disease
Background/Purpose: Rheumatoid arthritis (RA) patients have 50% increased risk of heart failure (HF) vs non-RA patients with a distinct phenotype, preserved ejection fraction on transthoracic…Abstract Number: 0289 • ACR Convergence 2021
Developing a Score to Predict Preclinical Interstitial Lung Disease in Patients with Rheumatoid Arthritis – a Cross-Sectional Study from the ESPOIR Cohort
Background/Purpose: Interstitial lung disease (ILD) can be detected in 20% to 60% of patients with rheumatoid arthritis (RA) on high-resolution computed-tomography (HRCT) chest scan and…Abstract Number: 0463 • ACR Convergence 2021
Treatment Persistence Among Medicare Beneficiaries with Seropositive Rheumatoid Arthritis Initiating Biologic or Targeted Synthetic DMARDs
Background/Purpose: Recent exploratory clinical trial and retrospective studies1 suggest that patients with seropositive RA (rheumatoid factor [RF]+ and/or anti-cyclic citrullinated peptide [anti-CCP]+) treated with abatacept…Abstract Number: 0570 • ACR Convergence 2021
A Narrowed, but Persistent Mortality Gap: A National, Matched Cohort Study in U.S. Veterans with Rheumatoid Arthritis from 2000-2017
Background/Purpose: Rheumatoid arthritis (RA) is recognized to increase the risk of premature death. The impact of RA on survival varies across causes of death, though…Abstract Number: 0591 • ACR Convergence 2021
The Temporal Association Between Hospital Admissions, Disease-modifying Anti-rheumatic Drugs Usage and Direct Health Care Costs in Rheumatoid Arthritis Patients
Background/Purpose: Rheumatoid arthritis (RA) carries a substantial burden for patients and society in terms of morbidity, disability, and medical expenses. The Australian Pharmaceutical Benefits Scheme…Abstract Number: 0745 • ACR Convergence 2021
Patient-reported Outcomes and Safety Measures in Patients with Rheumatic Diseases Who Switched from Reference or Other Biosimilar Etanercept to Biosimilar Etanercept GP2015 and in Biologic-naïve Patients Starting a Treatment with GP2015: 12-month Interim Analysis from a Real-world Study
Background/Purpose: GP2015 is a biosimilar of etanercept (ETN). COMPACT is an ongoing, non-interventional study, evaluating the effectiveness, safety, and quality of life with GP2015 treatment…Abstract Number: 0797 • ACR Convergence 2021
Psychosocial Wellbeing and Illness Perceptions During the Early Disease Phase Predict Sustained Remission in Rheumatoid Arthritis
Background/Purpose: Patient-reported outcomes (PROs) relating to global psychosocial wellbeing are rarely assessed in clinical trials for rheumatoid arthritis (RA), and specifically not to tailor additional…Abstract Number: 0815 • ACR Convergence 2021
Implementing Treat to Target (TTT) for Rheumatoid Arthritis (RA) Through a Virtual Learning Collaborative (LC) Program During COVID
Background/Purpose: TTT has been shown in multiple RCTs to be an effective paradigm for managing RA, however TTT has not been uniformly implemented in US…Abstract Number: 0832 • ACR Convergence 2021
Consistency in Time to Response with Upadacitinib as Monotherapy or Combination Therapy and Across Patient Populations with Rheumatoid Arthritis
Background/Purpose: Upadacitinib (UPA) has demonstrated efficacy in patients with moderate-to-severe rheumatoid arthritis (RA) across various patient populations.1–4 This post hoc analysis aimed to evaluate the…Abstract Number: 0958 • ACR Convergence 2021
Risk Factors for Major Adverse Cardiovascular Events in Patients Aged ≥ 50 Years with RA and ≥ 1 Additional Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors
Background/Purpose: To identify independent risk factors for major adverse cardiovascular (CV) events (MACE) in ORAL Surveillance (NCT02092467), a long-term, randomized, open-label, non-inferiority, Phase 3b/4 safety…Abstract Number: 1017 • ACR Convergence 2021
Osteoclast-Specific Transmembrane Protein (OC-STAMP) Regulates Osteoclastogenesis and Inhibits Inflammation in an Acute Arthritis Model
Background/Purpose: Dendritic Cell (DC)-Specific Transmembrane Protein (STAMP) expressed by osteoclast precursors is required for cell-cell fusion in the formation of the osteoclast (OC) polykaryon. Genetic…
- 1
- 2
- 3
- …
- 86
- Next Page »